Hormonal
Retatrutide (4-12 mg weekly) produces early, sustained changes in appetite and eating behaviors (reduced hunger, increased satiety, smaller portions) within 8 weeks, leading to significant weight loss and improved physical/emotional well-being in adults with obesity.
If you have obesity or overweight with health complications, retatrutide (4-12mg weekly) significantly reduces hunger and increases fullness within weeks, leading to substantial weight loss (up to 24%) and improved energy/mobility. It addresses the biological barriers to lifestyle changes that often cause failure with diet/exercise alone. Expect some frustration if results are slower than hoped or side effects occur, but the behavioral shift in eating is a key benefit.
Thirty-one of 36 retatrutide-treated participants reported changes in eating behaviors within the trial’s first 8 weeks. Participants described eating less often or smaller portions, feeling hungry less often, feeling full after eating... Participants reported improvements in mobility or ability to perform physical activities, energy levels, social activities involving food, exercise, and leisure activities, as well as reduction in clothing size.
Why this rating
Phase 2 double-blind placebo-controlled trial with qualitative exit interviews (N=40), though qualitative nature limits generalizability of subjective reports.
Source
Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial
Iris Goetz et al. · Obesity Pillars · 2025
DOI 10.1016/j.obpill.2025.100220
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →